Gilead Sciences reports $7.8 billion revenue for quarter ended June 30, 2026, up 10.2%

ยท GILD

Gilead Sciences reported revenue of $7.8 billion for the quarter ended June 30, 2026, an increase of 10.2% from the same quarter a year earlier ($7.08 billion).

For the same period it posted a net loss of $10.5 billion, or $-8.45 per diluted share (1.56 a year earlier).

That is a net margin of -134.5%.

On Sanad's AAOIFI Standard 21 screen, Gilead Sciences is currently compliant: interest-bearing debt is 12.4% of market capitalisation (limit 30%), and impure income is 1.2% of revenue (limit 5%).

Source: 10-Q filed with the U.S. Securities and Exchange Commission on August 6, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Gilead Sciences news